Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients
- 22 February 2020
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 40 (5), 1052-1061
- https://doi.org/10.1111/liv.14415
Abstract
Background & Aims Nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis B (CHB) are common liver diseases. Concurrent NAFLD may affect antiviral treatment outcomes in CHB patients. The aim of this study is to investigate the impact of NAFLD on complete viral suppression [(CVS), HBV DNA < 20‐100 IU/mL] and/or biochemical response [(BR), ALT of ≤ 25 U/L for females; 35 U/L for males] in CHB patients who received oral antiviral therapy. Methods A retrospective study of 555 treated CHB patients (187 NAFLD; 368 non‐NAFLD) from 2000 to 2016 at a USA medical center. NAFLD was diagnosed by imaging and/or histology after ruling out secondary causes of hepatic steatosis. Results The majority of patients were male (60.7%), Asian (87.56%), and HBeAg‐negative (66.7%). NAFLD patients compared to non‐NAFLD were more likely HBeAg negative (74.3% vs. 62.8%, P=0.02), hypertensive (33.2% vs. 22.8%, P=0.009), male (67.4% vs. 57.3%, P=0.02) with a higher mean BMI (25.4±4.3 vs. 23.8±4.0 kg/m2, P0.05), but NAFLD had higher cumulative rates of CVS+BR, compared with non‐NAFLD patients (32.5% vs. 22.8%, P=0.03). In multivariate analyses, NAFLD was not independently associated with CVS and/or BR outcomes. Receipt of entecavir or tenofovir (versus older therapies) and lower baseline HBV DNA or higher ALT were positively associated with achieving CVS or BR. Conclusion Concomitant NAFLD had no impact on the long‐term rates of CVS and/or BR in treated CHB patients.Keywords
This publication has 43 references indexed in Scilit:
- Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-UpPLOS ONE, 2013
- Association between Hepatic Steatosis and Entecavir Treatment Failure in Chinese Patients with Chronic Hepatitis BPLOS ONE, 2012
- Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-Year prospective studyVirology Journal, 2011
- Hepatic steatosis in hepatitis B virus infected patients: Meta‐analysis of risk factors and comparison with hepatitis C infected patientsJournal of Gastroenterology and Hepatology, 2011
- Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infectionLiver International, 2011
- Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis BWorld Journal of Gastroenterology, 2011
- Two Patterns of Alanine Aminotransferase Increase to Predict Long-Term Viral Response in Chronic Hepatitis B Patients: Virus- or Host-Induced?Antiviral Therapy, 2010
- Hepatic steatosis and fibrosis in young men with treatment‐naïve chronic hepatitis BLiver International, 2009
- A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patientsLiver International, 2008
- Hepatitis C and SteatosisArchives of Medical Research, 2007